rec-2282
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT05130866)
Timeline
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06858865 | Phase 1 | Jul 12, 2025 | Addpharma Inc. |
| NCT06747936 | Phase 3 | Dec 31, 2024 | Addpharma Inc. |
| NCT05130866 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2021 | Recursion Pharmaceuticals Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Addpharma Inc. | For profit | 2 | 2 | 2 | 2024 |
| Recursion Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1